EODData

MEMBERSHIP REGISTER LOG IN

FRA, 67N0: GENOR BIOPHARMA DL-00002

06 Nov 2025
LAST:

0.2940

CHANGE:
 0.01		OPEN:
0.2940		HIGH:
0.2940		ASK:
0.0000		VOLUME:
3.8K
CHG(%):
3.92		PREV:
0.3060		LOW:
0.2940		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 250.29400.29400.29400.29403.8K
05 Nov 250.30600.30600.30600.30603.8K
04 Nov 250.31800.31800.31800.31803.8K
03 Nov 250.33400.33400.33400.33403.8K
31 Oct 250.32200.32200.32200.32203.8K
30 Oct 250.32000.32000.32000.32003.8K
29 Oct 250.33400.33400.33400.33403.8K
28 Oct 250.33200.33200.33200.33203.8K
27 Oct 250.34600.34600.34600.34603.8K
24 Oct 250.33400.33400.33400.33403.8K

COMPANY PROFILE

Name:GENOR BIOPHARMA DL-00002
About:Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat solid tumours. It also develops GB226, which is in Phase III clinical trial; GB261, which is in Phase I/II clinical trial for NHL; and GB263T that is in Phase I/II clinical trial for NSCLC. In addition, the company develops GB221, which is in Phase III clinical trial for HER2+ 1L/2L+ mBC; GB223 that is in Phase I clinical trial for GCTB, PMO; GB241 that is in Phase III clinical trial for 1L DLBCL; and GB251, which is in Phase I clinical trial for HER2+ 1L/2L+ mBC. Further, the company's product candidates that are in pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for cancer treatment. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
Sector:Healthcare
Industry:Biotechnology
Address:Building 6, Shanghai, China, 201203
Website:https://www.genorbio.com
ISIN:KYG3871A1004

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:31.80 
Price to Sales:0.74 
Price to Book:0.15 
Profit Margin:0.13 
Operating Margin:-2.04 
Return on Assets:0.02 
Return on Equity:0.03 
Revenue:27.29M 
EBITDA:1.82M 
Shares:522.75M 
Market Cap:153.69M 

TECHNICAL INDICATORS

MA5:0.317.1%
MA10:0.3210.2%
MA20:0.3520.3%
MA50:0.4243.5%
MA100:0.3726.4%
MA200:0.303.1%
RSI14:23.75 
WPR14:-100.00 
MTM14:-0.07
ROC14:-0.20 
ATR:0.01 
Week High:0.3313.6%
Week Low:0.290.0%
Month High:0.4759.9%
Month Low:0.293.1%
Year High:0.5793.9%
Year Low:0.1594.7%
Volatility:37.60